Kybella

ClearlyDerm / Cosmetic Dermatology / Kybella

KYBELLA^® is a prescription medicine and is the only FDA-approved injectable treatment used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.” Submental fullness is a gathering of excess fat beneath the chin, commonly known as “double chin.” Once treated, the fat cells are destroyed and leave your body through natural processes.

Your ClearlyDerm provider will create a tailored treatment plan based on your chin profile. At each treatment, you will be given multiple small injections under your chin. The number of injections required depends on the size of the treatment area and your desired results. You may receive up to 6 treatment sessions, spaced at least 1 month apart. Many patients experience visible results in 2 to 4 KYBELLA^® treatments. 59% of patients received 6 treatments in clinical studies.

Kybella is commonly used to treat:

The appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin

What To Expect

Length Of Time For The Procedure: 15-30 minutes depending on the size and area being treated. Up to 6 treatments, one month apart.
Recovery Time: There is little to no downtime following the procedure. Some patients can experience slight bruising, swelling, numbness and redness, which typically subsides soon after the procedure.
Final Results Of The Procedure: 12-24 weeks depending on the amount of secessions
Duration of Kybella: fat cells are permanently removed

Before & After Photos

KYBELLA® (deoxycholic acid) injection 10 mg/mL Before-and-After Photos

Results are represented over the course of treatment; not all treatments are shown. Number of treatments is tailored* to the amount of fat below the chin and aesthetic goals; 59% of patients received 6 KYBELLA® treatments in clinical studies.

*Multiple injections under the chin per treatment; up to 6 treatments at least 1 month apart.

KYBELLA® (deoxycholic acid) injection 10 mg/mLIndication and Important Safety Information

INDICATION

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS

Marginal Mandibular Nerve Injury

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising

In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures

To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

ADVERSE REACTIONS

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.